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A Booster Dose Enhances
Immunogenicity of the COVID-19 Vaccine
Candidate ChAdOx1 nCoV-19 in Aged Mice
Alyssa Silva-Cayetano,1,5 William S. Foster,1,5 Silvia Innocentin,1,5 Sandra Belij-Rammerstorfer,2,6
Alexandra J. Spencer,2,6 Oliver T. Burton,1 Sigrid Fra-Bidó,1 Jia Le Lee,1 Nazia Thakur,4
Carina Conceicao,4 Daniel Wright,2 Jordan Barrett,2 Nicola Evans-Bailey,3 Carly Noble,3 Dalan Bailey,4
Adrian Liston,1 Sarah C. Gilbert,2 Teresa Lambe,2,7,* and Michelle A. Linterman1,7,8,*Context and Significance
Effective COVID-19 vaccines will
play a central role in the exit
strategy from the worldwide
pandemic. However, older
persons often do not generate
protective immunity upon
vaccination due to age-
dependent changes in their
immune system. Because older
people are more likely to have
poor clinical outcomes after
SARS-CoV-2 infection, vaccine
strategies that elicit an optimal
immune response in older bodies
are urgently required.
Researchers from the Babraham
Institute , the Jenner Institute, and
the Pirbright Institute in the UK
performed pre-clinical testing of
the COVID-19 vaccine candidate
ChAdOx1 nCoV-19 in aged mice
to assess how aging influences the
immune response to this vaccine.
The results show that a ‘‘prime-
boost’’ vaccine regime enhances
immunogenicity in aged mice,
indicating that this approach is a
rational strategy for vaccinatingSUMMARY
Background: The spread of SARS-CoV-2 has caused a worldwide
pandemic that has affected almost every aspect of human life. The
development of an effective COVID-19 vaccine could limit the
morbidity and mortality caused by infection and may enable the relax-
ation of social-distancing measures. Age is one of the most significant
risk factors for poor health outcomes after SARS-CoV-2 infection; there-
fore, it is desirable that any new vaccine candidates elicit a robust im-
mune response in older adults.
Methods: Here, we use in-depth immunophenotyping to characterize
the innate and adaptive immune response induced upon intramuscular
administration of the adenoviral vectored ChAdOx1 nCoV-19 (AZD-
1222) COVID-19 vaccine candidate in mice.
Findings: A single vaccination generates spike-specific Th1 cells, Th1-
like Foxp3+ regulatory T cells, polyfunctional spike-specific CD8+
T cells. and granzyme-B-producing CD8 effectors. Spike-specific IgG
and IgM are generated from both the early extrafollicular antibody
response and the T follicular helper cell-supported germinal center re-
action, which is associated with the production of virus-neutralizing
antibodies. A single dose of this vaccine generated a similar type of im-
mune response in aged mice but of a reduced magnitude than in
younger mice. We report that a second dose enhances the immune
response to this vaccine in aged mice.
Conclusions: This study shows that ChAdOx1 nCoV-19 induces both
cellular and humoral immunity in adult and aged mice and suggests a
prime-boost strategy is a rational approach to enhance immunogenicity
in older persons.
Funding: This study was supported by BBSRC, Lister institute of Preven-
tative Medicine, EPSRC VaxHub, and Innovate UK.older persons.INTRODUCTION
The current Coronavirus Disease 2019 (COVID-19) pandemic is caused by the zoo-
notic severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).1,2 The
pandemic has affected almost every aspect of human life and will continue to do
so until effective vaccines or therapeutics are developed. SARS-CoV-2 infection is
initiated when the trimeric ‘‘spike’’ glycoprotein on the virion surface binds angio-
tensin-converting enzyme 2, allowing viral entry and initiating viral replication.3 AfterMed 2, 1–20, February 12, 2021 ª 2020 The Author(s). Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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clinical outcomes, from negligible or mild symptoms to critical disease resulting in
death.4 One of the main risk factors for severe disease and death is age.4–6 There-
fore, development of a successful COVID-19 vaccine should aim to be effective in
older adults.7,8 However, age-related changes in the immune system mean that
older individuals often do not generate protective immunity after vaccination.9–12
The effectiveness of COVID-19 vaccine candidates in older adults will ultimately be
determined in clinical trials. Yet, pre-clinical studies in aged animals can be used to
test alternative vaccine strategies or dosing regimens and can be used to inform clin-
ical strategy. Despite aging occurring on different timescales in mice and people,
many of the cellular and molecular changes that occur are conserved between the
species.13,14 The response to vaccination is no exception15,16; after vaccination,
both aged mice (>20 months old) and older humans have reduced vaccine-specific
antibody formation, an impaired type I interferon (IFN) response and fewer T follic-
ular helper cells.17–20 This impaired immune response to vaccination in older individ-
uals has been linked with reduced protection against subsequent infection.9,21–23
Importantly, interventions that enhance the immunogenicity of vaccines in aged
mice are also effective in humans.17,22,24,25
ChAdOx1 nCoV-19 is a chimpanzee adeno (ChAd)-vectored vaccine that encodes
the full-length spike protein of SARS-CoV-2. Vaccination with ChAdOx1 nCoV-19
elicits spike-specific T cells that produce IFN-g and anti-spike antibodies in mice,
pigs, macaques, and people.26–28 Here, we demonstrate that a single dose of ChA-
dOx1 nCoV-19 elicits a B and T cell response in 3-month-old adult mice, with forma-
tion of plasma cells, germinal centers, and T follicular helper cells contributing to
anti-spike antibody production. The development of humoral immunity is comple-
mented by the formation of polyfunctional SARS-CoV-2 spike-specific Th1 cells
and CD8+ T cells. In aged 22-month-old mice, a similar cellular and humoral
response was observed upon vaccination, but the formation of germinal centers
and spike-specific CD8+ T cells that secrete granzyme B was impaired. Administra-
tion of a second dose enhanced the germinal center response, spike-specific IgG
and virus-neutralizing antibody titer, and no deficit in spike-specific granzyme-B-
producing CD8+ T cells was observed in aged mice. Together, this indicates that
the immunogenicity of ChAdOx1 nCoV-19 can be enhanced in older individuals
through the use of a prime-boost vaccination strategy.
RESULTS
Intramuscular Immunization with ChAdOx1 nCoV-19 Activates Antigen-
Presenting Cells in the Iliac Lymph Node and Spleen
To map where antigen drains upon immunization, 3-month-old adult mice were
immunized in the right quadriceps muscle with 20 nm fluorescent nanoparticles
that freely drain into lymphoid organs.29 24 h after injection, confocal microscopy re-
vealed fluorescent nanoparticles in the medial iliac lymph node (iLN) and the spleen
of all immunized mice (Figure S1A). These data suggest the iLN and spleen are sites
of antigen drainage.
To characterize the early events of the immune response to ChAdOx1 nCoV-19
vaccination, we immunized adult C57BL/6 mice and assessed the induction of IFN
signaling as well as the expansion of antigen-presenting cell (APC) populations at
day 1 and 2 post-immunization. At the site of immunization, expression of the
type I and 2 IFN-inducible genes, Mx1 and Gbp2, respectively, was detected by
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ventional dendritic cells (cDC2s), Langerhans cells, macrophages, and cDC1s were
quantified by flow cytometry, and all subsets were activated in response to
ChAdOx1 nCoV-19 (Figures S1C–S1E; gating strategy from30). These data demon-
strate that the ChAdOx1 nCoV-19 vaccine activates several APC populations
required for the initiation of cell-mediated and humoral immunity.17,31,32
ChAdOx1 nCoV-19 Immunization Stimulates B Cell Activation and
Differentiation
To assess the adaptive immune response to ChAdOx1 nCoV-19 in detail, we used a
high-dimensional flow cytometry panel that contained antibodies that recognize
multiple molecules used to define different lymphocyte subsets and their activation
status (Key Resources Table). Mice were immunized with either ChAdOx1 nCoV-19
or PBS, and the immune response was assessed 7, 14, and 21 days later. t-distributed
stochastic neighbor embedding (tSNE) and FlowSOM analysis grouped B cells into
five clusters (Figure 1A). Cluster 1 corresponded to naive B cells, which were present
in both ChAdOx1 nCoV-19 and PBS-immunized mice, and four additional clusters
which were over-represented in ChAdOx1 nCoV-19-immunized mice. The clusters
represent activated B cells that express CD69+ (cluster 2) or CD86+ (cluster 5), a clus-
ter of CD138+IRF4+ antibody-secreting plasma cells (cluster 3) and Bcl6+GL-7+
germinal center B cells (cluster 4). Manual biaxial gating of these populations (Fig-
ure S2A) showed that ChAdOx1 nCoV-19 immunization induced a B cell response
in the draining lymph node and spleen (Figures 1B and 1C), with early B cell activa-
tion and plasma cell formation occurring in the first week after immunization, and the
germinal center response persisting over the three weeks assessed (Figures 1B–1G).
Formation of T follicular helper and T follicular regulatory cells accompanied the
germinal center response (Figures 1H and 1I). Antibodies binding the SARS-CoV-2
spike protein were induced by vaccination, and, as expected, the temporal induction
of anti-spike IgM was faster than that of IgG, and serum IgA antibodies were not
observed at high titer (Figure 1J). Of note, the method of quantification does not
facilitate direct comparison between IgG and IgM titer. A mix of anti-spike IgG anti-
body subtypes was observed, with IgG2 and IgG1 subclasses persisting at later time
points. At all time points, a predominantly Th1 dominant response (IgG2) was
measured (Figure 1K). The mean (and standard deviation) value for ratio of IgG2/
IgG1 on day 7 was 4.8 (1.4), on day 14 was 2.3 (0.5), and on day 21 was 2.8 (1.8).
This demonstrates that ChAdOx1 nCoV-19 immunization stimulates B cell activation
and differentiation, culminating in the production of anti-spike antibodies.
ChAdOx1 nCoV-19 Immunization Induces Th1 Cell and Th1-like Treg
Formation
To investigate how ChAdOx1 nCoV-19 immunization affects CD4+ T cells beyond
the germinal center-associated subsets, tSNE analysis followed by manual gatingFigure 1. ChAdOx1 nCoV-19 Induces a Plasma Cell and Germinal Center B Cell Response
(A) tSNE/FlowSOM analyses of CD19+ B cells from 3-month-old (3mo) mice 7 days after immunization with ChAdOx1 nCoV-19 or PBS; on the heatmap,
red indicates high expression, and yellow indicates low expression.
(B and C) Heatmaps of the manually gated B cell populations indicated at 7, 14, and 21 days after immunization in the iliac lymph node (B) and spleen (C);
the gating strategy for these populations is shown in Figure S2. Here, the frequency of each cell subset in each ChAdOx1 nCoV-19-immunized mouse
has been expressed as the log2 fold change over the average frequency in PBS-immunized mice (n = 5).
(D–J) Bar charts showing the total number of plasma cells (D), CD69+IgD+ B cells (E), proliferating non-germinal center B cells (F) and germinal center B
cells (G) at the indicated time points after immunization. Number of T follicular helper (H) and T follicular regulatory cells (I) at the indicated time points
post-immunization. Serum anti-spike IgM, IgG, and IgA (J) antibodies 7, 14, and 21 days after immunization.
(K) Pie charts indicating the mean abundance of each IgG antibody subclass in the serum at the indicated time points after immunization.
In (D)–(J), the bar height corresponds to the mean and each circle represents one biological replicate. p values are calculated using a Student’s t test
with Holm-Sidak multiple testing correction; for ELISA, data analyses were done on log transformed values.
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showed that vaccination induced populations of T cells that express markers associ-
ated with T follicular helper cells (cluster 5), Th1 cells (cluster 2), Tbet-expressing
Th1-like Tregs (cluster 3), and CD69+-activated Treg cells (cluster 4) (Figure 2A).
The conventional CD4+ T cell response to ChAdOx1 nCoV-19 was characterized
by early activation and proliferation, as well as the formation of CXCR3+ Th1 cells
(Figures 2A–2F). The Foxp3+ regulatory T cell response was characterized by early
expression of Ki67, indicative of proliferation, and the differentiation of CXCR3+
Th1-like cells (Figures 2C and 2G). To further characterize CD4+ T cell responses af-
ter vaccination, cells from the iLN were restimulated with PdBu/ionomycin and cyto-
kine production was assessed. IL-2, TNF-a, IL-10, and IFN-g were induced by cells
isolated from animals that had been ChAdOx1 nCoV-19 vaccinated, with no differ-
ence observed in Th17-associated IL-17 or the Th2-associated cytokines IL-4 and IL-
5 (Figure 2H; Figure S3A–S3C). The spike specificity of this Th1-associated response
in the draining lymph node was confirmed by restimulation of cells with peptide
pools from SARS-CoV-2 spike protein (Figure 2I). In the spleen, spike-specific IL-2,
TNF-a, and IFN-g-producing CD4+ T cells were observed, with triple producers per-
sisting 21-days after immunization (Figure 2J, Figure S3D), consistent with previous
work.26 Therefore, ChAdOx1 nCoV-19 vaccination induces an early formation of Th1
cells and Th1-like Treg cells accompanied by the induction of spike-specific Th1-
skewed cytokine-secreting cells.ChAdOx1 nCoV-19 Induces a CD8+ T Cell Response
tSNE analysis of CD8+ T cells from the iLNs of ChAdOx1 nCoV-19-immunized and
PBS control mice revealed distinct clustering 7 days after immunization. There
were five CD8+ T cell clusters that were more abundant in ChAdOx1 nCoV-19-immu-
nized mice, than in PBS-immunized animals. Cluster 2 contains markers consistent
with a CXCR5+ follicular CD8 cell population, cluster 3 is characterized by CXCR3
expression a marker of tissue homing, clusters 4 and 5 expresses CD69 and
CD62L consistent with CD8 cells at an early stage of activation, and cluster 6 ex-
presses high levels of CXCR4 a chemokine receptor that facilitates bone-marrow
localization of CD8+ T cells (Figure 3A). Together, this highlights that a diverse array
of CD8+ T cell subsets are induced by ChAdOx1 nCoV-19. In order to understand
how the response evolves over time, manual gating of different CD8+ T cell popula-
tions (Figure S2D), including those identified in the tSNE analysis, was done on sam-
ples taken 7, 14, and 21 days after immunization. In the iLN and spleen, the CD8+
T cell response to ChAdOx1 nCoV-19 was characterized by an increase in Ki67
expression, the upregulation of the activation markers CD69, CXCR3, and PD-1,
as well as the formation of CD44+CD62L– antigen-experienced T cells (FiguresFigure 2. ChAdOx1 nCoV-19 Induces a Th1-Dominated CD4 Cell Response
(A) tSNE/FlowSOM analyses of CD4+ T cells from 3-month-old (3mo) mice 7 days after immunization with ChAdOx1 nCoV-19 or PBS; on the heatmap,
red indicates high expression, and yellow indicates low expression.
(B and C) Heatmaps of the manually gated CD4+Foxp3– (B) and Foxp3+CD4+ (C) T cell populations indicated at 7, 14, and 21 days after immunization in
the iliac lymph node (right) and spleen (left), the gating strategy for these populations is shown in Figure S2. Here, the frequency of each cell subset in
each ChAdOx1 nCoV-19-immunized mouse has been expressed as the log2 fold change over the average frequency in PBS-immunized mice (n = 5).
(D–G) Bar charts showing the number of CD69+CD62L+CD44–CD4+Foxp3– (D), Ki67+CD4+Foxp3– (E) CXCR3+ non-Tfh cells (F) and CXCR3+ Th1-like
Treg cells (G) CD4+ cells in the iliac lymph node of ChAdOx1 nCoV-19 or PBS-immunized mice, at the indicated time points post-immunization.
(H) Analysis of cytokine production 6 h after PdBu/ionomycin stimulation of iliac lymph node cells from 3-month-old mice 7 days after immunization with
ChAdOx1 nCoV-19 or PBS.
(I and J) Stacked bar plots show the number of CD4+Foxp3– cells singly or co-producing IFN-g, IL-2, or TNF-a in the iLN 7 days after immunization (I) or
spleen at the days post-immunization (J); 6 h after restimulation with SARS-CoV-2 peptide pools, each bar segment represents the mean and the error
bars the standard deviation.
In (D)–(G), the bar height corresponds to the mean and each circle represents one biological replicate. p values are calculated using a Student’s t test
with Holm-Sidak multiple testing correction.
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Figure 3. ChAdOx1 nCoV-19 Induces a CD8 T Cell Response
(A) tSNE/FlowSOM analyses of CD8+ T cells from 3-month-old (3mo) mice 7 days after immunization with ChAdOx1 nCoV-19 or PBS; on the heatmap red
indicates high expression, and yellow indicates low expression.
(B) Heatmap of the manually gated CD8 T cell populations indicated at 7, 14, and 21 days after immunization in the iliac lymph node and spleen; the
gating strategy for these populations is shown in Figure S2. The frequency of each cell subset in each ChAdOx1 nCoV-19-immunized mouse has been
expressed as the log2 fold change over the average frequency in PBS-immunized mice (n = 5). Crossed boxes indicate that there were none of that cell
type for that mouse.
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T cells 7 days after vaccination, cells from the iLN were restimulated with PdBu/ion-
omycin. There was a significant production of granzyme B, IL-2, TNF-a, and IFN-g in
ChAdOx1 nCOV-19-vaccinatedmice compared to PBS-immunizedmice (Figure 3G).
The spike specificity of cytokine-producing cells in the draining lymph node was
confirmed by restimulation with SARS-CoV-2 peptide pools (Figure 3H). Restimula-
tion of splenocytes with SARS-CoV-2 spike protein peptide pools from SARS-CoV-2
showed that spike-specific cytokine-producing CD8+ T cells form in response to im-
munization (Figure 3I; Figures S4A and S4B). Spike-specific granzyme-B-producing
CD8+ T cells formed early and tended not to co-produce cytokines (Figure 3I).
Both single and multiple cytokine-producing spike-specific cells formed at all time
points, with TNF-a and IFN-g being the dominant cytokines expressed (Figure 3I;
Figure S4C). With this dosing regimen, these data demonstrate that ChAdOx1
nCoV-19 stimulates a spike-specific CD8+ T cell response that peaks around the first
week after vaccination.A Prime-Boost Strategy Corrects Dysregulated CD8 T Cell Priming in Aged
Mice
To assess the CD8+ T cell response to ChAdOx1 nCoV-19 immunization in the
context of aging, we immunized 3- and 22-month-old mice and enumerated the
CD8+ T cell types altered by vaccination (in Figure 3) 9 days after immunization (Fig-
ure 4A). In the draining iLN, CD8+ T cells from aged mice expressed markers of acti-
vation and proliferation in response to ChAdOx1 nCoV-19. Unlike in younger adult
mice, the frequency of CXCR3+ cells or antigen-experienced cells did not increase in
aged mice, compared to the PBS-vaccinated group (Figures 4B–4D). At this early
time point, the frequency of central memory T cells was not altered in either younger
adult or aged mice by ChAdOx1 nCoV-19 vaccination (Figure 4E). In the spleen,
fewer Ki67+ CD8+ T cells were observed in agedmice after ChAdOx1 nCoV-19 vacci-
nation, compared to younger adult mice (Figure 4F). The formation of spike-specific
CD8+ T cells was assessed by restimulating splenocytes with SARS-CoV-2 spike pro-
tein peptide pools. Aged mice had a near absence of spike-specific granzyme-B-
producing CD8+ T cells, but production of IFN-g and TNF-a was not significantly
impaired compared to younger mice (Figure 4G). Despite a trend to lower cytokine
production by CD8+ T cells in agedmice, the proportion of polyfunctional spike-spe-
cific CD8+ T cells was not significantly diminished in aged mice after ChAdOx1
nCoV-19 vaccination (Figure 4H). This demonstrates that a single dose of ChAdOx1
nCoV-19 induces an altered CD8+ T cell response in aged mice characterized pri-
marily by a failure to form spike-specific granzyme-B-producing effector cells.
To determine whether a second dose could improve this response, we administered
a booster dose of ChAdOx1 nCoV-19 1 month after prime immunization (Figure 4I).
Nine days after boost, an increase in Ki67+ CD8+ T cells was not observed in the
draining iLN (Figure 4J), possibly due to the kinetics of the secondary response be-
ing faster than the primary. A significant increase in CXCR3+ CD8+ T cells and(C–F) Bar charts showing the number of Ki67+ (C), antigen-experienced CD44+CD62L– (D), CXCR3+ (E), and PD-1+CD44+ (F) CD8 cells in the iliac lymph
node of ChAdOx1 nCoV-19 or PBS-immunized mice, at the indicated time points post-immunization.
(G) Analysis of cytokine production 6 h after PdBu/ionomycin stimulation of iliac lymph node cells from 3-month-old mice 7 days after immunization with
ChAdOx1 nCoV-19 or PBS.
(H and I) Stacked bar plots show the number of CD8+ cells singly or co-producing Granzyme B, IFN-g, IL-2, or TNF-a 6 h after restimulation with SARS-
CoV-2 peptide pools, in the iLN 7 days after immunization (H) or spleen 7, 14, and 21 days after immunization (I); each bar segment represents the mean
and the error bars the standard deviation.
In (C)–(F), the bar height corresponds to the mean, and each circle represents one biological replicate. p values are calculated using a Student’s t test
with Holm-Sidak multiple testing correction.
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the proportion of central memory cells in either age group (Figures 4K–4M). Assess-
ment of spike-specific T cells showed that the booster dose of ChAdOx1 nCoV-19
rescued the production of granzyme-B-producing CD8+ T cells in aged mice (Fig-
ure 4N). IFN-g production and cytokine polyfunctionality were similar to that
following prime immunization (Figures 4O and 4P). This demonstrates that
ChAdOx1 nCoV-19 is immunogenic in aged mice, and a booster dose can correct
the age-dependent defect in the formation of spike-specific granzyme-B-producing
CD8+ T cells.Prime-Boost Enhances the CD4+ T Cell Response to ChAdOx1 nCoV-19 in
Aged Mice
Nine days after primary immunization of aged mice (Figure 5A), an increase in
Ki67+CD4+ T cells and CXCR3-expressing Th1 cells was observed in the draining
lymph node of ChAdOx1 nCoV-19-immunized mice compared to PBS-immunized
control mice (Figures 5B and 5C). This was accompanied by an increase in the fre-
quency of Th1-like Tregs in both adult and aged mice (Figure 5D). An increased fre-
quency of these cell types was likewise observed in the spleen in response to
ChAdOx1 nCoV-19 immunization in both adult and aged mice (Figures 5E–5G). It
is notable that, by these measurements, the response in aged mice is comparable
to that in younger adults. The spike-specific CD4+ T cell response was assessed by
restimulating splenocytes with SARS-CoV-2 spike protein peptide pools. As in
young mice (Figure 2), the response in aged mice to ChAdOx1 nCoV-19 was Th1
dominated; however, there were fewer spike-specific cytokine-producing cells in
aged mice 9 days after a single immunization (p < 0.001, Figures 5H and 5I).
A booster dose of ChAdOx1 nCoV-19 administered 1 month after prime (Figure 5J)
stimulated Ki67 expression and the formation of CXCR3+CD44+ Th1 cells but not
CXCR3+ Th1-like Treg cells in the draining lymph node of aged mice (Figures 5K–
5M). In the spleen, the booster dose did not enhance the frequency of Ki67+
CD4+ T cells or the formation of CXCR3+ conventional or regulatory T cells in adult
or aged mice (Figures 5N–5P). In contrast to the response to primary immunization,
the number of spike-specific cytokine-producing cells was comparable in adult and
aged mice after booster immunization (Figures 5Q and 5R). Together, this indicatesFigure 4. A Prime-Boost Strategy Enhances the CD8 T Cell Response to ChAdOx1 nCoV-19 in Aged Mice
(A) Cartoon of prime immunization strategy.
(B–E) Percentage of Ki67+ (B), CXCR3+ (C), antigen-experienced CD44+CD62L– (D), and central memory CD44+CD62L+ (E) CD8+ T cells in the draining
iliac lymph node from 3-month-old (3mo) or 22-month-old (22mo) mice 9 days after immunization with ChAdOx1 nCoV-19 or PBS.
(F) Percentage of proliferating Ki67+ splenic CD8+ T cells in 3-month-old (3mo) or 22-month-old (22mo) mice 9 days after immunization with ChAdOx1
nCoV-19 or PBS.
(G and H) Number of CD8+ T cells producing granzyme B (GZMB), IFN-g, IL-2, or TNF-a 6 h after restimulation with SARS-CoV-2 peptide pools in (G), and
the number of single and double cytokine-producing CD8+ T cells are represented in stacked bar charts. Spleen cells are taken from 3-month-old (3mo)
or 22-month-old (22mo) mice 9 days after immunization with ChAdOx1 nCoV-19 or PBS.
(I) Cartoon of prime-boost immunization strategy.
(J–M) Percentage of Ki67+ (J), CXCR3+ (K), antigen-experienced CD44+CD62L– (L), and central memory CD44+CD62L+ (M) CD8+ T cells in the draining
iliac lymph node from 3-month-old or 22-month-old mice 9 days after immunization with ChAdOx1 nCoV-19 or PBS.
(N–P) Percentage of proliferating Ki67+ splenic CD8+ T cells in 3-month-old or 22-month-old mice 9 days after immunization with ChAdOx1 nCoV-19 or
PBS. Number of CD8+ cells producing Granzyme B (N) or IFN-g (O) 6 h after restimulation with SARS-CoV-2 peptide pools in (P), and the number of
single and double cytokine-producing CD8+ T cells are represented in stacked bar charts. Spleen cells are taken from 3-month-old or 22-month-old
mice 9 days after immunization with ChAdOx1 nCoV-19 or PBS.
The bar height in B-G, J-O corresponds to the median and each circle represents one biological replicate. In (H), (P), each bar segment represents the
mean and the error bars the standard deviation. The Shapiro-Wilk normality test was used to determine whether the data are consistent with a normal
distribution, followed by either an ordinary one-way ANOVA test for data with a normal distribution or a Kruskal-Wallis test for non-normally distributed
data alongside a multiple comparisons test. Data are representative of two independent experiments (n = 4-8 per group/experiment).
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Clinical and Translational Articlethat the CD4+ T cell response to ChAdOx1 nCoV-19 immunization is largely intact in
aged mice, with a slight deficiency in antigen-specific cytokine production that can
be enhanced by a booster immunization.Aged Mice Have an Impaired Germinal Center Response after Primary
Immunization
Themajority of clinically available vaccines are thought to provide protection by elic-
iting humoral immunity. Therefore, it was important to quantify the B cell response to
ChAdOx1 nCoV-19 vaccination in the context of aging. Early antibody production
after vaccination arises from antibody-secreting cells generated in the extrafollicular
plasma cell response, which is fast but typically short lived.33 A comparable early
plasma cell response was detected in the iLN of younger adult and aged mice after
immunization (Figures 6A and 6B), although there was an increase in the proportion
of IgM+ plasma cells in aged mice (Figure 6C). An intact plasma cell response was
coupled with an increase in anti-spike antibodies 9 days after immunization. These
were of only slightly lower titer in aged mice, and of similar IgG subclass distribution
to younger animals, indicative of a predominantly Th1-dominated response (Figures
6D–6F).
Long-lived antibody-secreting cells typically arise from the germinal center
response.34 The percentage, but not total number, of germinal center B cells was
reduced in aged mice compared to younger adult mice after ChAdOx1 nCoV-19
vaccination (Figures 6G and 6H). Like the plasma cell response, there were more
IgM+ germinal center B cells in aged mice (Figure 6I). An increase in T follicular help-
er cells, but not T follicular regulatory cells, accompanied the lymph node germinal
center response in adult and aged mice (Figures 6J and 6K). In the spleen, germinal
centers were easily visualized by microscopy in adult mice 9 days after ChAdOx1
nCoV-19 vaccination but were conspicuously absent in aged mice (Figure 6L; Fig-
ure S5). Quantification of splenic germinal centers by flow cytometry confirmed
impaired germinal center formation in aged mice (Figures 6N and 6O). This was
accompanied by fewer proliferating non-germinal center B cells and T follicular help-
er cells in aged mice (Figures 6P and 6Q). As in the draining lymph node, splenic T
follicular regulatory cells were not induced by ChAdOx1 nCoV-19 vaccination at this
time point (Figure 6R). The impact of an impaired germinal center response on spike-
specific antibodies was observed 28 days after immunization, with aged mice having
lower titers of anti-spike IgM and IgG (Figures 6S and 6T) but a similar profile of IgGFigure 5. The CD4 Cell Response to ChAdOx1 nCoV-19 in Aged Mice
(A) Cartoon of prime immunization strategy.
(B–G) Percentage of proliferating Ki67+ (B), CXCR3+CD44+ CD4 T cells (C) and CXCR3+CD44+Foxp3+ Treg cells (D) in the draining iliac lymph node.
Percentage of proliferating Ki67+ (E), CXCR3+CD44+ CD4 T cells (F) and CXCR3+CD44+Foxp3+ Treg cells (G) in the spleen of 3-month-old or 22-month-
old mice 9 days after immunization with ChAdOx1 nCoV-19 or PBS.
(H and I) Number of CD4+Foxp3– cells producing IFN-g, IL-2, IL-4, IL-5, IL-17, or TNF-a 6 h after restimulation with SARS-CoV-2 peptide pools in (I), and
the number of single and multiple cytokine-producing CD4+ T cells are represented in stacked bar charts.
(J) Cartoon of prime-boost immunization strategy.
(K–M) Percentage of proliferating Ki67+ (K), CXCR3+CD44+ CD4 T cells (L), and CXCR3+CD44+Foxp3+ Treg cells (M) in the draining iliac lymph node.
(N–P) Percentage of Ki67+ CD44+ (N), CXCR3+CD44+ CD4+Foxp3– T cells (O), and CXCR3+CD44+Foxp3+ Treg cells (P) in the spleen of 3-month-old or
22-month-old mice 9 days after immunization with ChAdOx1 nCoV-19 or PBS.
(Q and R) Number of CD4+Foxp3– T cells producing IFN-g, IL-2, IL-4, IL-5, IL-17, or TNF-a 6 h after restimulation with SARS-CoV-2 peptide pools in (R),
and the number of single and multiple cytokine-producing CD4+ T cells are represented in stacked bar charts. In (B–H) and (K–P), the bar height
corresponds to the median, and each circle represents one biological replicate.
In (I) and (R), each bar segment represents the mean and the error bars the standard deviation. The Shapiro-Wilk normality test was used to determine
whether the data are consistent with a normal distribution, followed by either an ordinary one-way ANOVA test for data with a normal distribution or a
Kruskal-Wallis test for non-normally distributed data alongside a multiple comparisons test. Data are representative of two independent experiments
(n = 4–8 per group/experiment).
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Clinical and Translational Articlesubclasses (Figure 6U). Together, these data indicate that, while a single of dose of
ChAdOx1 nCoV-19 can induce comparable extrafollicular plasma cell responses be-
tween younger adult and aged mice, the germinal center response is compromised
with age.A Second Dose of ChAdOx1 nCoV-19 Boosts Humoral Immunity in Aged Mice
To test whether a prime-boost strategy can enhance the B cell response in aged
mice, a prime-boost approach was taken (Figure 7A). Nine days after boost, there
were Ki67+ non-germinal center B cells, plasma cells and germinal center B cells in
the draining lymph nodes of aged mice (Figures 7B–7H). Notably, the magnitude
of the germinal center response was larger in aged mice than in younger adult
mice after boost (Figures 7F–7H), and this was associated with increased T follicular
helper and T follicular regulatory cell numbers (Figures 7I and 7J). A germinal center
response was not observed in the spleen of either adult or aged mice 9 days after
booster immunization (Figure 7K). This demonstrates that a second dose of ChA-
dOx1 nCoV-19 can enhance the B cell response in aged mice. This improvement
in the B cell response corresponded to an increase in anti-spike IgG, without skewing
IgG subclasses, antibodies in every aged mouse that was given a booster immuniza-
tion (Figures 7L–7O). The post-boost ratio of IgG2/IgG1 was 3.7 (3.0) in younger
adult and 2.6 (1.6) in aged mice (mean and standard deviation). The functional effect
of the humoral immunity after both prime and boost immunizations was measured
by SARS-CoV-2 pseudotyped virus microneutralization assay. Nine days after prime
immunization, SARS-CoV-2 neutralizing antibodies were at a lower titer in agedmice
than measured in adult mice (Figure 7P). Nine days after boost, neutralizing anti-
bodies were detectable in all aged mice and had been boosted 8-fold compared
to post-prime, although the titer was lower than in younger adult mice (Figure 7P).
The SARS-CoV-2 neutralizing antibody titer positively correlated with anti-spike
IgG titer in aged mice, indicating that the main limitation in age-dependent humoral
immunity is quantity, rather than function (Figure 7R). This demonstrates that a
booster dose of ChAdOx1 nCoV-19 can improve anti-spike humoral immunity in
older mice.DISCUSSION
The development of an effective anti-SARS-CoV-2 vaccine represents an opportunity to
limit the health, social, and economic consequences of the current pandemic. SinceFigure 6. Impaired B Cell Responses after ChAdOx1 nCoV-19 Immunization of Aged Mice
(A and B) B cell response in 3-month-old (3mo) or 22-month-old (22mo) mice 9 days after immunization with ChAdOx1 nCoV-19 or PBS. Flow cytometric
evaluation of the percentage (A) and number (B) of plasma cells in the iliac lymph node.
(C) Pie charts showing the proportion of IgM+IgD– (orange) and switched IgM–IgD– (blue) plasma cells from (A) and (B).
(D and E) Serum IgM (D) and IgG (E) anti-spike antibodies 9 days after immunization.
(F) Pie charts showing the proportion of anti-spike IgG of the indicated subclasses in the serum 9 days after immunization.
(G and H) Percentage (G) and number (H) of germinal center B cells in the iliac lymph node.
(I) Pie charts showing the proportion of IgM+IgD– (orange) and switched IgM–IgD– (blue) germinal center cells from (G) and (H).
(J–M) Number of T follicular helper (J) and T follicular regulatory (K) cells in the draining lymph node. Confocal images of the spleen of ChAdOx1 nCoV-
19-immunized mice of the indicated ages; in (L), the scale bars represent 500 mm; in (M), the scale bars represent 50 mm. IgD+ B cell follicle are in green,
CD3+ T cells in magenta, Ki67+ cells in blue, and CD35+ follicular dendritic cells in white.
(N and O) Percentage (N) and number (O) of splenic germinal center B cells.
(P) Percentage of Ki67+ B cells in the spleen.
(Q and R) Number of splenic T follicular helper (Q) and T follicular regulatory (R) cells.
Serum IgM (S) and IgG (T) anti-spike antibodies and IgG subclasses (U) 28 days after immunization. For all bar graphs, the bar height corresponds to the
median and each circle represents one biological replicate. The Shapiro-Wilk normality test was used to determine whether the data are consistent with
a normal distribution, followed by either an ordinary one-way ANOVA test for data with a normal distribution or a Kruskal-Wallis test for non-normally
distributed data alongside a multiple comparisons test, for ELISA data analyses were done on log transformed values. Data are representative of two
independent experiments (n = 4–8 per group/experiment).
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Figure 7. A Booster Immunization Enhances the B Cell Response to ChAdOx1 nCoV-19 Immunization in Aged Mice
(A) Scheme of the prime-boost immunization protocol.
(B) Percentage of Ki67+ B cells in the draining lymph node.
(C and D) Percentage (C) and number (D) plasma cells in the iliac lymph node.
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Clinical and Translational Articleolder adults aremore likely to have severe health outcomes after infection, a vaccination
strategy that provides protection for this group is particularly desirable. Here, we pro-
vide themost detailed immunophenotyping analysis to date of how themurine immune
system following ChAdOx1 nCoV-19 vaccination. This vaccine stimulates both cellular
and humoral immunity. Vaccination of younger adult mice triggers formation of spike-
specific polyfunctional CD8+ and Th1 cells that persist for at least 21 days after immuni-
zation. The first surge of antibodies come from short-lived plasma cells, that produce
low levels of neutralizing antibodies. Germinal centers and T follicular helper cells are
established later in the response, which contribute to longer term antibody titers.
One dose of this vaccine stimulates an immune response in aged mice, but it is of
reduced magnitude compared to that seen in younger adult animals. Importantly, the
data presented here show that a second homologous immunization was able to
enhance the B cell, helper T cell, and CD8+ T cell response in aged mice. In people,
the same prime-boost approach had an acceptable safety profile and enhanced humor-
al immunity,28 indicating that this is a rational vaccination approach for use in the older
members of our communities—arguably the sector of society most in need of an effec-
tive vaccine to prevent COVID-19.
Strategies that are able to enhance humoral immunity in older individuals are key to
vaccine efficacy, particularly as in some respiratory infections, a higher titer of anti-
bodies are required to be protective.35,36 Antibody-secreting cells can form from
two cellular pathways, but these are not equal in terms of quality or longevity. The
extrafollicular response produces an initial burst of antibodies early after antigenic
challenge. This response is short lived with no additional diversification of the B
cell repertoire, and thus its contribution to long-term immunity is minimal.33 The
germinal center reaction is a specialized microenvironment that produces memory
B cells and long-lived antibody secreting plasma cells with somatically mutated
immunoglobulin (Ig) genes.34,37,38 The germinal center is the only cellular source
of long-lived plasma cells39 and the only known site where the B cell response can
be altered in response to antigen. Nine days after ChAdOx1 nCoV-19 immunization,
the formation of plasma cells was comparable in young and aged mice, a time at
which the majority of plasma cells derive from the extrafollicular response.39 By
contrast, the germinal center response was diminished in aged mice, which is a
well-described deficit of the older immune system after vaccination.17,40 This indi-
cates that poor germinal center formation is themajor barrier that must be overcome
to improve humoral immunity in older individuals. A booster dose of ChAdOx1
nCoV-19 enhanced the magnitude of the germinal center response in aged mice,
to a greater extent than it did in younger animals. This may be because younger
mice have produced higher titers of anti-vaccine vector antibodies, which limits
the action of a second dose.(E) Pie charts showing the proportion of IgM+IgD– (orange) and switched IgM–IgD– (blue) plasma cells from (B) and (C).
(F and G) Percentage (F) and number (G) of germinal center B cells in the iliac lymph node.
(H) Pie charts showing the proportion of IgM+IgD– (orange) and switched IgM–IgD– (blue) germinal center cells from (F) and (G).
(I and J) Number of T follicular helper (I) and T follicular regulatory (J) cells in the draining lymph node.
(K) Percentage (K) of splenic germinal center B cells.
(L–O) Serum anti-spike IgM (L), IgG (M), and IgG subclasses (N and O) prior to boost (day 29) and 9 days after boost immunization.
(P and Q) SARS-CoV-2 neutralizing antibody titers in sera were determined by micro neutralization test, expressed as reciprocal serum dilution to inhibit
pseudotyped virus entry by 50% (IC50). Samples below the lower limit of detection (LLoD) are shown as half of the LLoD.
(R) Linear regression of serum dilution to inhibit pseudotyped virus entry by 50% (IC50 Log10) and serum anti-spike ELISA titer (Log10) in 22-month-old
mice, 9 days post-boost. For all bar graphs, the bar height corresponds to the median and each circle represents one biological replicate. The Shapiro-
Wilk normality test was used to determine whether the data are consistent with a normal distribution, followed by either an ordinary one-way ANOVA
test for data with a normal distribution or a Kruskal-Wallis test for non-normally distributed data alongside a multiple comparisons test. For ELISA, data
analyses were done on log transformed values. In (B)–(O), data are shown from one of two independent experiments (n = 4–8 per group/experiment); in
(P)–(R), the data are pooled from two experiments.
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Clinical and Translational ArticleAnother feature of the aged germinal center reaction is reduced selection of high-
affinity B cells, resulting in a diminished quality of the response in aging.19 Whether
the further diversification and affinity-based selection of the B cell receptor is impor-
tant for protective humoral immunity to SARS-CoV-2 has yet to be established. How-
ever, antibodies isolated from spike-specific B cells from convalescent COVID-19
patients can be both potently neutralizing and have low levels of somatic hypermu-
tation,41–43 indicating that extensive somatic hypermutation is not required for anti-
SARS-CoV-2-neutralizing antibody formation. Therefore, the main barrier to
inducing protective humoral immunity to SARS-CoV-2 in older people may be an
issue of enhancing the magnitude, rather than quality, of the germinal center
response. Our study shows this can be achieved in aged mice by giving a second
dose of the vaccine.
A rapid recall of memory CD8+ T cells in response to viral infections complements
the humoral response by promoting efficient pathogen clearance and this be-
comes particularly important in scenarios where the protective ability or magni-
tude of neutralizing antibodies is compromised.44 A single dose of ChAdOx1
nCoV-19 vaccine induces a CD8+ T cell response in both adult and aged mice.
There was, however, a profound defect in the generation of spike-reactive CD8+
T cells that produced granzyme B, a key cytotoxic effector molecule produced
by effector CD8+ T cells. This failure to generate granzyme B+ CD8+ T cells is a
common feature in aging, previously observed in aged mice after West Nile Virus
infection45 and in aged monkeys infected with SARS-CoV.46 A similar trend for
fewer granzyme B+ CD8+ cells in older people was observed after influenza vacci-
nation.47 Consistent with reduced expression of granzyme B in T cells from older
adults, T cells taken from older adults have an impaired ability to kill influenza in-
fected cells ex vivo.48 In a small study of older people, induction of granzyme B
after influenza vaccination was a correlate of protection in older adults.36 Here,
we demonstrate that a second dose of ChAdOx1 nCoV-19 was able to correct
the defective granzyme B+ CD8+ T cell response in aged mice, indicating that
two doses of this vaccine is a better approach to enhance the cellular immune
response in older bodies.
ChAdOx1 nCoV-19 is currently being trialed in older adults as part of a phase III
trial, which will ultimately determine whether it is an effective vaccine for this de-
mographic. Immunization of people over 55 years of age with adenovirus type-
5(Ad5)-vectored COVID-19 vaccine resulted in lower antibody titers in the older
age group, suggesting that adenoviral vectored vaccine strategies may require
more than one dose in older people.49 However, as pre-existing immunity to
Ad5, a naturally occurring human tropic adenovirus, can inhibit the response to
this vaccine, it is possible that the reduced immunogenicity of this vaccine is
due to an increased prevalence of antibodies to the vaccine vector in this age
group. By contrast, the presence of anti-ChAdOx1 antibodies in the general pop-
ulation is low.50 The work presented here demonstrates that one dose of this vac-
cine is immunogenic in aged mice, but this response can be significantly
improved with a second booster dose. Given that a second dose of ChAdOx1
nCoV-19 is immunogenic with expected reactogenicity profile in humans,28 this
may be a viable strategy to enhance immunogenicity and possibly efficacy in
older people.
Limitations of Study
This study used aged mice as a pre-clinical model to test the immunogenicity of ChA-
dOx1 nCoV-19 in older bodies. One limitation of this study was that SARS-CoV-2Med 2, 1–20, February 12, 2021 17
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Clinical and Translational Articleinfections were not performed to test the protection conferred by vaccination. SARS-
CoV-2 does not naturally infect mice; to circumvent this limitation, mouse adapted
strains have been generated.51,52 In order to bind to the mouse angiotensin-converting
enzyme 2, SARS-CoV-2 requires amino acid substitutions in the receptor binding
domain of the spike protein. As such, challenge with mouse adapted SARS-CoV-2
frequently mismatches vaccine encoded antigens and may not reflect real-world sce-
narios. The data presented in this manuscript show that a second dose of ChAdOx1
nCoV-19 increases anti-spike IgG titer and SARS-CoV-2 pseudovirus neutralizing anti-
body titer in aged mice, both of which are correlates of protection against SARS-CoV-
2 infection in species that are susceptible to the wild-type virus.53,54
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HEK293T ATCC ATCC CRL-3216; RRID:CVCL_0063
Experimental Models: Organisms/Strains
Mouse C57BL/6Babr Babraham Institute C57BL/6Babr
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
SARS-CoV-2 Spike BioBasic Wuhan strain QHR63290.2
pcDNA3.1 Invitrogen Cat# V79020
Human Angiotensin-converting enzyme 2 (ACE2) expression plasmid Addgene Plasmid#1786; RRID:Addgene_1786
Software and Algorithms
FlowJo Treestar https://www.flowjo.com/; RRID: SCR_008520
Volocity PerkinElmer https://www.perkinelmer.com:443/
category/image-analysis-software; RRID: SCR_002668
Glomax-Multi detection system Promega TM297, Cat#E7081; RRID: SCR_015575
GraphPad Prism GraphPad https://www.graphpad.com/; RRID: SCR_002798
CFX Manager software BioRad CFX Manager Software #1845000; RRID: SCR_017251
SOFTmax PRO Molecular Devices https://www.moleculardevices.com/
products/microplate-readers/; RRID: SCR_014240
R https://www.r-project.org; RRID: SCR_001905
Other
Breeder and Grower CRM(P)VP diet Special diet services Cat# 801722
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Lead Contact
Further information and requests for resources and reagents should be directed to
and will be fulfilled by the Lead Contact, Michelle Linterman (michelle.linterman@
babraham.ac.uk).
Materials Availability
This project did not generate new unique reagents.
Data and Code Availability
This project did not generate any new code or novel datasets.
EXPERIMENTAL MODEL AND SUBJECT DETAIL
Mouse housing and husbandry
C57BL/6Babr mice were bred, aged and maintained in the Babraham Institute Biolog-
ical Support Unit. No primary pathogens or additional agents listed in the Federation of
European Laboratory Animal Science Association recommendations55 were detected
during health monitoring surveys of the stock holding rooms. Ambient temperature
was 19–21C and relative humidity 52%. Lighting was provided on a 12 hr light:
12 hr dark cycle including 15 min ‘dawn’ and ‘dusk’ periods of subdued lighting. After
weaning, mice were transferred to individually ventilated cages with 1–5 mice per
cage. Mice were fedMouse Breeder and Grower CRM (P) VP diet (Special Diet Services)
ad libitum and received seeds (e.g., sunflower, millet) at the time of cage-cleaning as
part of their environmental enrichment. All mouse experimentation was approved by
the Babraham Institute Animal Welfare and Ethical Review Body. Animal husbandry
and experimentation complied with existing European Union and United Kingdom
Home Office legislation and local standards (PPL: P4D4AF812). Young mice were 10–
12 weeks old, and aged mice 93–96 weeks old when experiments were started. Mice
that had tumors, which can occur in aged mice, were excluded from the analysis.
METHODS DETAILS
Immunisation and tissue sampling
Mice were immunized in the right quadriceps femoris muscle with 50mL of either
1x108 infectious units of ChAdOx1 nCoV-19 in phosphate buffered saline (PBS)Med 2, 1–20.e1–e8, February 12, 2021 e5
ll
OPEN ACCESS
Please cite this article in press as: Silva-Cayetano et al., A Booster Dose Enhances Immunogenicity of the COVID-19 Vaccine Candidate ChA-
dOx1 nCoV-19 in Aged Mice, Med (2020), https://doi.org/10.1016/j.medj.2020.12.006
Clinical and Translational Articlealone, 50mL 0.02mm yellow-green fluorescent Carboxylate-Modified Microspheres
(Invitrogen # F8787) in phosphate buffered saline (0.5% solids, final injected concen-
tration). At the indicated time points post vaccination, blood, the right medial iliac
lymph node, spleen and right quadriceps femoris muscle were taken for analysis.
Flow cytometry
For T and B cell flow cytometric stains a single cell suspension was prepared from the
iliac lymph node and half the spleen was generated by pressing the tissues through a
70 mm mesh in 2% FBS in PBS. Cell numbers and viability were determined using a
CASY TT Cell Counter (Roche). 2 3 106 cells were transferred to 96-well plates for
antibody staining. Samples were blocked with 100 mL of 2.4G2 Fc Block (made in
house) for 20 min at 4C. Cells were then stained with surface antibody mix for
2hrs at 4C and then were fixed with the eBiosciences Foxp3/Transcription Factor
Staining Buffer (#00-5323-00) for 30 min at 4C. Cells were then washed with 1x Per-
meabilisation buffer (eBioscience #00-8333-56) twice and stained with intracellular
antibody mix in 1x Permeabilisation buffer at 4C overnight. For cytokine staining,
splenic cells were stimulated with a pool of SARS-CoV-2 spike protein immunodomi-
nant domain peptides, (Miltenyi Biotec #130-126-700) at a 0.6 mMconcentration (ap-
prox.1mg/ml), while lymph node cells were stimulated with 0.5mg/ml of Phorbol
12,13 dibutyrate (PdBu, Tocris Bioscience, #), 0.75mg/ml of Ionomycin calcium salt
(Tocris Bioscience, #), both in warm complete RPMI (10% FCS, 1% Pen/Strep, 1%
glutamine, 1% sodium pyruvate, 1%MEMNAA, 1%HEPES and 55 mM-2-mercaptoe-
thanol) for 4hrs at 37C, 5%CO2. Cytokine secretion was then blocked with 22mg/ml
of Brefeldin A (Tocris Bioscience, #) in warm complete RPMI for 2hrs at 37C, 5%
CO2. The cells were then stained with surface antibody mix for 20 minutes at 4C
and were subsequently fixed with 2% formaldehyde for 30min at room temperature.
After two wash steps with 1x Permeabilisation buffer (eBioscience #00-8333-56), the
cells were stained with intracellular antibody mix in 1x Permeabilisation buffer, sup-
plemented with 20% 2.4G2 Fc Block at 4C overnight. Following overnight staining,
samples were washed twice with 1x Permeabilisation buffer and once with 2% FBS in
PBS and acquired on a CytekTM Aurora. Cells for single color controls were prepared
in the samemanner as the fully stained samples. The antibodies used for surface and
overnight staining are listed in the Key Resources Table.
Manual gating of flow cytometry data was done using FlowJo v10 software (Tree
Star). tSNE, FlowSOM and heatmap analysis were performed on iLN samples from
day 7 post-vaccination using R (version 4.0.2) using code that has previously been
described56. The antibodies used for surface staining are listed in Key Resources
Table.
Confocal imaging
For imaging of germinal centers, half of the spleen was fixed in periodate-lysine-
paraformaldehyde (PLP) containing 1% (v/v) PFA (Sigma #P6148), 0.075 M L-Lysine
(Sigma #L5501), 0.37MNa3PO4 (pH 7.4) (Sigma #342483) and 0.01MNaIO4 (Sigma
#210048), for 4 hr at 4C. For imaging yellow-green fluorescent Carboxylate-Modi-
fied Microspheres (Invitrogen # F8787), lymph nodes and spleen were fixed in BD
Cytofix/Cytoperm (BD Cat #554722), diluted 1 in 4 in PBS. After fixation, all tissues
were dehydrated in 30% sucrose (Sigma #S0389) overnight, embedded in Optimum
Cutting Temperature (OCT) medium (VWR #25608–930) on dry ice and stored at
80C. The frozen tissues were cut into 10 mm sections using a cryostat (Leica Bio-
systems) at20C and again stored at80C. For imaging yellow-green fluorescent
carboxylate-codified microspheres, slides were first air-dried and then washed in
PBS three times after which DAPI staining was performed (Invitrogen #D1306;e6 Med 2, 1–20.e1–e8, February 12, 2021
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Slides were then washed three times with PBS and coverslips were mounted on
the slides using Hydromount mounting medium (National Diagnostics #HS-106).
For antibody stains, the slides were first air-dried and then hydrated in 0.5% Tween
20 in PBS (PBS-T). The slides were blocked in PBS containing 2% BSA and 10% goat
serum for 2hrs, washed three times with PBS-T and then permeabilised with PBS con-
taining 2% Triton X (Sigma #X100) for 45min. Following three wash steps with PBS-T,
the slides were stained with primary antibody mix, which included AF647-conju-
gated rat anti-mouse IgD (clone 11-26 c.2a, Biolegend; 1:200), FITC-conjugated
rat anti-mouse Ki67 (clone SolA15, Invitrogen; 1:100), rat anti-mouse biotin-conju-
gated CD21/35 (clone 8D9, ThermoFisher Scientific; 1:400) and hamster anti-mouse
CD3ε (clone 500A2, ThermoFisher Scientific; 1:200), in PBS-T containing 1% BSA at
4C overnight. The next day, slides were washed three times with PBS-T and incu-
bated with secondary antibody mix, which included AF568-conjugated goat anti-
hamster IgG (Thermofisher, 1:1000) and BV421-conjugated Streptavidin (Biolegend,
1:1000), in PBS-T containing 2%goat serum for 2hr at room temperature. Slides were
then washed three times with PBS-T, PBS and dH2O and coverslips were mounted
using Hydromount mounting medium (National Diagnostics #HS-106). Images
were acquired using a Zeiss 780 confocal microscope with 10x and 20x objectives
and analyzed using ImageJ.
Enzyme-linked immunosorbent assay (ELISA)
Standardized ELISA was performed to detect SARS-CoV-2 FL-S protein – specific an-
tibodies in sera. MaxiSorp plates (Nunc) were coated with 100 or 250 ng/well FL-S
protein overnight at 4 C for detection of IgG or IgM and IgA, respectively, prior
to washing in PBS/Tween (0.05% v/v) and blocking with Blocker Casein in PBS
(Thermo Fisher Scientific) for 1 h at room temperature (RT). Standard positive serum
(pool of mouse serum with high endpoint titer against FL-S protein), individual
mouse serum samples, negative and an internal control (diluted in casein) were incu-
bated for 2 hours at room temperature for detection of specific IgG or 1h at 37C for
detection of specific IgM or IgA. Following washing, bound antibodies were de-
tected by addition of alkaline phosphatase (AP)-conjugated goat anti-mouse IgG
(Sigma-Aldrich) for 1h at room temperature or addition of AP-conjugated goat
anti-mouse IgM or IgA (Abcam and Sigma-Aldrich, respectively) and addition of
p-Nitrophenyl Phosphate, Disodium Salt substrate (Sigma-Aldrich). An arbitrary
number of ELISA units were assigned to the reference pool and optical density
values of each dilution were fitted to a 4-parameter logistic curve using SOFTmax
PRO software. ELISA units were calculated for each sample using the optical density
values of the sample and the parameters of the standard curve.
The IgG subclass ELISA were performed according to the protocol described for
detection of specific IgM or IgA in the serum. In addition, all serum samples were
diluted to 1 total IgG ELISA unit and then detected with anti-mouse IgG subclass-
specific secondary antibodies (Southern Biotech or Abcam). The results of the IgG
subclass ELISA are presented using optical density values instead of the ELISA units
used for the total IgG ELISA. The ratio of IgG2/IgG1 was calculated for each animal as
sum of optical density values (IgG2b + IgG2c) divided by the optical density value of
IgG1 and represented as mean values with standard deviation (SD).
Micro neutralisation test using lentiviral-based pseudotypes bearing the
SARS-CoV-2 Spike
Lentiviral-based SARS-CoV-2 pseudotyped viruses were generated in HEK293T cells
incubated at 37C, 5% CO2 as previously described
27. Briefly, cells were seeded at aMed 2, 1–20.e1–e8, February 12, 2021 e7
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lows: 500 ng of SARS-CoV-2 spike, 600 ng p8.91 (encoding for HIV-1 gag-pol),
600 ng CSFLW (lentivirus backbone expressing a firefly luciferase reporter gene),
in Opti-MEM (GIBCO) along with 10 mL PEI (1 mg/mL) transfection reagent. A ‘no
glycoprotein’ control was also set up using the pcDNA3.1 vector instead of the
SARS-CoV-2 S expressing plasmid. The following day, the transfection mix was re-
placed with 3 mL DMEM (Dulbecco’s Modified Eagle’s medium) with 10% fetal
bovine serum (DMEM-10%) and incubated for 48 and 72 hours, after which superna-
tants containing pseudotyped SARS-CoV-2 (SARS-CoV-2 pps) were harvested,
pooled and centrifuged at 1,300 x g for 10 minutes at 4C to remove cellular debris.
Target HEK293T cells, previously transfected with 500 ng of a human Angiotensin-
converting enzyme 2 (ACE2) expression plasmid (Addgene, Cambridge, MA, USA)
were seeded at a density of 2 3 104 in 100 mL DMEM-10% in a white flat-bottomed
96-well plate one day prior to harvesting SARS-CoV-2 pps. The following day, SARS-
CoV-2 pseudotyped viruses were titrated 10-fold on target cells, and the remainder
stored at 80C. For micro neutralisation tests, mouse sera were diluted 1:20 in
serum-free media and 50 mL was added to a 96-well plate in triplicate and titrated
2-fold. A fixed titerd volume of SARS-CoV-2 pseudotyped viruses was added at a
dilution equivalent to 105 signal luciferase units in 50 mL DMEM-10% and incubated
with sera for 1 hour at 37C, 5% CO2 (giving a final sera dilution of 1:40). Target cells
expressing human ACE2 were then added at a density of 2 x 104 in 100 mL and incu-
bated at 37C, 5% CO2 for 72 hours. Firefly luciferase activity was then measured
with BrightGlo luciferase reagent and a Glomax-Multi+ Detection System (Promega,
Southampton, UK). Pseudovirus neutralization titers were expressed as the recip-
rocal of the serum dilution that inhibited luciferase expression by 50% (IC50).QUANTIFICATION AND STATISTICAL ANALYSIS
All experiments were performed either twice or three times with 3–8 mice per group.
Data was first tested for Gaussian distribution using a Shapiro-Wilk test. Then data
that was consistent with a normal distribution was analyzed with either a Student’s
t test for comparing two dataset, or one-way ANOVA test for data with multiple
groups. If the data did not follow a normal distribution then a Mann-Whitney test
was used for comparing two datasets and a Kruskal Wallis test for multiple compar-
isons. For ELISA data p values were generated on log transformed data. All p values
shown are adjusted for multiple comparisons where multiple tests were performed
on the same data. Analyses were performed within the Prism v8 software
(GraphPad).e8 Med 2, 1–20.e1–e8, February 12, 2021
